Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase

Bone

Volumn 48, Issue 2, 2011, Pages 259-266

  Stresing, Verena ^a,b   Fournier, Pierrick G ^a,b   Bellahcène, Akeila ^c   Benzaïd, Ismahène ^a,b   Mönkkönen, Hannu ^a,b,d   Colombel, Marc ^a,b   Ebetino, F Hal ^e   Castronovo, Vincent ^c   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e Warner Chilcott   (United States)

Author keywords

Angiogenesis; Bisphosphonate; FPPS; Risedronate; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; ISOPENTENYL DIPHOSPHATE; MEVALONIC ACID; NE 10790; NE 58025; NE 58051; PLACEBO; RISEDRONIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; CASTRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROSTATE; RAT; VASCULAR RING;

EID: 78650976566     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.09.035     Document Type: Article

References (35)

1. Fournier P.G., Stresing V., Ebetino F.H., Clézardin P. How do bisphosphonates inhibit bone metastasis in vivo?. Neoplasia 2010, 12:571-578.
2. Coleman R. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-166.
3. Stresing V., Daubiné F., Benzaid I., Mönkkönen H., Clézardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257:16-35.
4. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsäläinen J., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147:437-445.
5. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
6. Kunzmann V., Bauer E., Feurle J., Weißinger F., Tony H.P., Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
7. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102:2310-2311.
8. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
9. Wood J., Bonjean K., Ruetz S., Bellahcène A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
10. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002, 8:1080-1084.
11. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003, 9:2893-2897.
12. Melani C., Sangaletti S., Barazzetta F.M., Werb Z., Colombo M.P. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67:11438-11446.
13. Tang X., Zhang Q., Shi S., Yen Y., Li X., Zhang Y., et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 2010, 126:90-103.
14. Ribatti D., Nico B., Mangieri D., Maruotti N., Longo V., Vacca A., et al. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 2007, 26:1094-1098.
15. Hashimoto K., Morishige K., Sawada K., Tahara M., Shimizu S., Ogata S., et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 2007, 354:478-484.
16. Bellahcène A., Chaplet M., Bonjean K., Castronovo V. Zoledronate inhibits alphavbeta3 and alphavbeta5 integrin cell surface expression in endothelial cells. Endothelium 2007, 14:123-130.
17. Hasmim M., Bieler G., Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 2007, 5:166-173.
18. Bezzi M., Hasmim M., Bieler G., Dormond O., Rüegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003, 278:43603-43614.
19. Deckers M.M.L., van Beek E.R., van der Pluijm G., Wetterwald A., van der Wee-Pals L., Cecchini M.G., et al. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Metab 2002, 17:998-1007.
20. Biver E., Vieillard M.H., Cortet B., Salleron J., Falgayrac G., Penel G. No anti-angiogenic effect of clinical dosing regimens of a single zoledronic acid injection in an experimental bone healing site. Bone 2010, 46:643-648.
21. Nicosia R.F., Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta: A quantitative assay of angiogenesis in vitro. Lab Investig 1990, 63:115-122.
22. Bisphosphonates Fleisch H. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42:919-944.
23. Inoue R., Matsuki N., Jing G., Kanematsu T., Abe K., Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkB pathway in osteosarcoma cells. Br J Pharmacol 2005, 146:633-641.
24. Jahnke W., Rondeau J.M., Cotesta S., Marzinzik A., Pellé X., Geiser M., et al. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 2010, 6:660-666.
25. Mönkkönen H., Kuokkanen J., Holen I., Evans A., Lefley D.V., Jauhiainen M., et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19:391-399.
26. Roelofs A.J., Jauhiainen M., Mönkkönen H., Rogers M.J., Mönkkönen J., Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009, 144:245-250.
27. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157:427-435.
28. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006, 13:7-26.
29. van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Löwik C.W.G.M., Papapoulos S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33:805-811.
30. Schmidt A., Rutledge S.J., Endo N., Opas E.E., Tanaka H., Wesolowski G., et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci USA 1996, 93:3068-3073.
31. Skorey K., Ly H.D., Kelly J., Hammond M., Ramachandran C., Huang Z., et al. How does alendronate inhibit protein-tyrosine phosphatases ?. J Biol Chem 1997, 272:22472-22480.
32. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
33. Plotkin L.I., Bellido T. Bisphosphonate-induced, hemichannel-mediated, anti-apoptosis through the Src/ERK pathway: a gap junction-independent action of connexin 43. Cell Adhes Commun 2001, 8:377-382.
34. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G.G., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51:2187-2195.
35. Ebetino F.H., Dunford J.E., Lundy M.W., Pozzi M., Xia Z., Dobson R., et al. A mirror image pair of bisphosphonate analogs further demonstrates the mode of binding of the bisphosphonates in farnesyl pyrophosphate synthase. Bone 2008, 42(S1):S36-S37.